On this page
Quick Reference
Overview and Recommendations
Background
- •Gastric cancer recurrence after curative resection occurs in three patterns, locoregional (anastomotic site, tumor bed, regional nodes), distant metastatic (liver, extra-abdominal sites), or peritoneal, each with distinct management implications. The Dutch D1D2 trial established that D2 lymphadenectomy reduces local recurrence from 22% to 12% and regional recurrence from 19% to 13% compared with D1 dissection, though with higher operative mortality (10% vs 4%); gastric-cancer-related death at 15 years was 48% (D1) vs 37% (D2).
- •The paradigm for managing recurrent disease has shifted from palliative chemotherapy alone to biomarker-driven therapy, with mandatory retesting of HER2, PD-L1 combined positive score (CPS), and microsatellite instability (MSI) at the time of recurrence, as expression can change from the primary tumor. The landmark REGATTA trial demonstrated that gastrectomy does not improve survival in patients with a single non-curable factor (liver, peritoneum, para-aortic nodes), establishing that systemic therapy is the backbone for distant metastatic disease.
- •Peritoneal metastases carry the worst prognosis but have shown sensitivity to regional approaches. The DRAGON-01 trial of intraperitoneal plus intravenous paclitaxel with S-1 improved median overall survival (OS) to 19.4 months vs 13.9 months with intravenous alone (HR 0.67). The GASTRIPEC-I trial of cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) showed no OS benefit in the full cohort, but progression-free survival (PFS) was significantly longer with HIPEC (7.1 vs 3.5 months), and patients achieving complete cytoreduction had improved OS.
- •Oligometastatic disease, defined as ≤3 metastases confined to a single organ or a single extra-regional lymph node station, with peritoneal cancer index (PCI) ≤6 for peritoneal-limited disease, represents a distinct subset where metastasis-directed local therapy (SBRT, metastasectomy, or conversion surgery) may improve survival. The OMEC consensus stratifies by disease-free interval (DFI): for metachronous OMD with DFI >2 years, upfront local treatment is an option; for synchronous or DFI ≤2 years, systemic therapy is given first, followed by restaging for local therapy.
- •Prognosis remains poor, but sequential systemic therapy offers meaningful benefit. A meta-analysis of salvage chemotherapy demonstrated a 36% reduction in the risk of death (HR 0.64) with second-line therapy vs best supportive care. The GC-RiskAssigner seven-gene signature (CDH1, ELOVL5, EGFR, PIP5K1B, FGF1, CD44v8.10, TBCEL) identifies high-risk patients with median OS 10.2 months vs 80.9 months for low-risk patients in the MAGIC trial (HR 5.1). Circulating tumor DNA (ctDNA) is a powerful adjunct for early detection, with 80.65% of recurrences detectable within 90 days before radiographic progression.
Evaluation
- •Suspect recurrent gastric cancer when any of the following symptoms develop in a patient with prior curative-intent therapy: dysphagia to solid food or liquids, vomiting, abdominal pain, chest pain, regurgitation, unexpected weight loss, or progressive hoarseness. Asymptomatic patients with pStage II/III disease should undergo risk-adapted surveillance, with the NCCN guideline preferred for pStage III (ICER $983/QALY).
- •Order contrast-enhanced CT (CECT) of the chest, abdomen, and pelvis as the initial imaging modality. The CT-derived extracellular volume fraction (CT-ECV) ≥56.9% predicts postoperative recurrence in pStage II-III disease (sensitivity 82.1%, specificity 61.9%). CT-based radiomic models (e.g., Radiomics-Clinical Integrated Risk Stratification, RSA) predict early recurrence (within 2 years) with AUC 0.870-0.873 in external validation.
- •If CECT is negative or equivocal, obtain 68Ga-FAPI PET/CT, which detects recurrence in additional patients (17.9% management change) and has pooled sensitivity 74% and specificity 89% for regional lymph node metastases. FAPI PET/CT parameters (total lesion FAP expression ≥188.88 SUVbw·cm³, FAPI-avid tumor volume ≥44.17 cm³) independently predict worse PFS and OS, respectively.
- •Perform re-biopsy of an accessible lesion to reassess HER2, PD-L1 CPS, and MSI status, as these can change between primary and recurrent disease. For patients with peritoneal metastases, diagnostic laparoscopy with PCI calculation is essential to confirm the extent of peritoneal disease and guide therapy (e.g., intraperitoneal chemotherapy vs systemic alone).
- •Assess ECOG performance status, disease-free interval (DFI) from initial therapy, number and sites of metastases, and serum albumin. For oligometastatic evaluation, confirm the definition: ≤3 metastases in a single organ or one extra-regional lymph node station; for peritoneal-limited, PCI ≤6. The OMEC consensus recommends systemic therapy first for synchronous OMD or metachronous OMD with DFI ≤2 years, then restaging; upfront local therapy is an option for metachronous OMD with DFI >2 years.
- •Obtain circulating tumor DNA (ctDNA) if available; ctDNA positivity within 90 days before radiographic recurrence has 80.65% sensitivity. Combining ctDNA with tumor markers (CEA, CA19-9, CA72-4, CA125, CA242) increases the overall positive rate to 94.9% and improves agreement with pathological response to 83.8%. Consider molecular profiling with GC-RiskAssigner signature, ATM expression, and CLDN18.2 expression for prognostic stratification and potential targeted therapy.
- •Rule out pseudoprogression or immune-related adverse events if the patient is on immunotherapy. For patients with peritoneal carcinomatosis, assess for symptomatic ascites, bowel obstruction, and nutritional status. A PCI >6 generally excludes patients from regional therapy trials and suggests polymetastatic disease.
Management
- •Initiate first-line systemic therapy for HER2-negative, PD-L1 CPS ≥5 disease with a platinum-fluoropyrimidine doublet plus an immune checkpoint inhibitor. Recommended regimen: oxaliplatin 130 mg/m² IV on day 1 plus capecitabine 1000 mg/m² orally twice daily on days 1-14 of a 21-day cycle, combined with nivolumab 360 mg IV every 3 weeks or pembrolizumab 200 mg IV every 3 weeks. Continue until progression or unacceptable toxicity.
- •For HER2-positive disease (IHC 3+ or 2+ with FISH amplification), add trastuzumab to the chemotherapy backbone: trastuzumab 8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks. For patients with MSI-high or dMMR, consider pembrolizumab monotherapy as first-line (if PD-L1 CPS ≥1) or second-line after progression on chemotherapy.
- •For peritoneal metastases without obstruction, use intraperitoneal plus intravenous paclitaxel with S-1: paclitaxel 50 mg/m² IV plus 20 mg/m² IP on days 1 and 8, combined with S-1 80 mg/m² orally daily on days 1-14 of a 21-day cycle (DRAGON-01 regimen). This improved median OS to 19.4 months vs 13.9 months with IV alone (HR 0.67). For patients achieving complete cytoreduction at CRS, consider HIPEC with mitomycin C or cisplatin (doses per institutional protocol).
- •After progression on first-line platinum-based therapy, use second-line therapy. For patients with platinum-free interval <6 months, start paclitaxel 80 mg/m² IV weekly (days 1, 8, 15 of a 28-day cycle) plus ramucirumab 8 mg/kg IV every 2 weeks (RAINBOW regimen). Alternatively, irinotecan 150 mg/m² IV every 2 weeks is an option (WJOG 4007: median OS 9.5 vs 8.4 months, not significant). For those with longer platinum-free interval, platinum re-challenge may be considered.
- •In the third-line refractory setting, start regorafenib 160 mg orally once daily on days 1-21 of a 28-day cycle (INTEGRATE: PFS 2.6 vs 0.9 months, HR 0.40). Alternatively, apatinib 850 mg orally once daily continuously (median OS 4.83 vs 2.5 months). For patients with low ATM expression, olaparib plus paclitaxel (olaparib 300 mg BID continuously, paclitaxel 80 mg/m² weekly) achieved median OS 13.1 months vs 8.3 months (HR 0.56).
- •For oligometastatic disease (≤3 metastases in one organ, PCI≤6), consider metastasis-directed therapy after systemic therapy. For liver/lung oligometastases, stereotactic body radiotherapy (SBRT) 45-51 Gy in 3 fractions (e.g., 48 Gy in 3 fractions) is an option. For isolated para-aortic lymph node recurrence, SBRT 45-51 Gy in 3 fractions produced complete response in 5/7 patients with 3-year OS 43%. For solitary liver metastasis, metastasectomy yields median OS 34 months. For peritoneal oligometastasis (PCI≤6), cytoreductive surgery (CRS) with HIPEC can achieve 5-year survival 30-50% in expert centers.
- •Avoid gastrectomy for palliation in patients with distant metastases (REGATTA: no benefit, HR 1.09). For locoregional recurrence not amenable to local therapy, second-line chemotherapy prolongs survival (HR 0.64). Salvage surgery for recurrence after non-curative ESD carries limited benefit (median survival 5 months).
- •Monitor for adverse effects: with trastuzumab deruxtecan (T-DXd) for HER2-positive disease, any-grade ILD occurs in 9.6% (grade ≥3 in 2.8%, grade 5 in 1.2%), with median onset 2.9 months, require vigilant monitoring. With regorafenib, monitor for hypertension, hand-foot skin reaction, and diarrhea. With intraperitoneal chemotherapy, monitor for catheter-related infections and bowel obstruction.
- •Integrate palliative care early for symptom management (pain, nausea, obstruction, ascites). Refer to clinical trials for novel agents (e.g., CLDN18.2-targeted therapy, ADCs, bispecific antibodies). Discharge criteria for supportive care: when ECOG PS ≥3, progressive disease despite third-line therapy, or patient declines further treatment.
Board Review — High Yield
- •REGATTA trial, Gastrectomy does NOT improve survival in patients with a single non-curable factor (liver, peritoneum, para-aortic nodes); HR 1.09.
- •DRAGON-01 trial, Intraperitoneal paclitaxel + S-1 improves OS in peritoneal metastases (19.4 vs 13.9 months, HR 0.67).
- •GASTRIPEC-I trial, CRS±HIPEC: no OS benefit overall, but PFS longer with HIPEC and benefit in complete cytoreduction subgroup.
- •68Ga-FAPI PET/CT, Superior to CT for detecting recurrence; detection rate 95% for primary, 97% for distant mets.
- •Oligometastatic definition, ≤3 metastases in one organ, PCI≤6; metachronous with DFI>2 years may benefit from upfront local therapy.
- •Re-biopsy at recurrence, Mandatory, as HER2, PD-L1, MSI status can change from primary tumor.
- •ctDNA surveillance, 80.65% of recurrences detectable within 90 days before radiographic progression.
- •GC-RiskAssigner, Seven-gene signature (CDH1, ELOVL5, etc.) stratifies risk: high-risk median OS 10.2 months, low-risk 80.9 months (HR 5.1).
- •Avoid gastrectomy, REGATTA: no survival benefit; gastrectomy for palliation not indicated.
- •T-DXd ILD, Any-grade ILD in 9.6%; median onset 2.9 months; monitor closely.
Deep Dive — Evidence Details
Patterns of Recurrence
- ▸D2 lymphadenectomy reduces locoregional recurrence from 22% to 12% compared to D1 dissection at 15-year follow-up [17].
- ▸Peritoneal recurrence is the most common distant pattern and carries a distinct management approach, with intraperitoneal chemotherapy showing improved PFS and MFS in selected patients [7][8].
- ▸Pattern of recurrence (locoregional vs distant vs peritoneal) dictates whether salvage surgery, radiotherapy, systemic therapy, or regional therapy is appropriate.
Recurrence of after curative-intent therapy follows one of three patterns, locoregional, distant metastatic, or peritoneal, and the pattern at presentation dictates the subsequent management algorithm. The 15-year follow-up of the Dutch D1D2 trial provides the most definitive surgical data: D2 lymphadenectomy reduced local recurrence from 22% to 12% and regional recurrence from 19% to 13% compared with D1 dissection, though D2 was associated with higher operative mortality (10% vs 4%) [17]A1b. Gastric-cancer-related death at 15 years was 48% in the D1 group versus 37% in the D2 group [17]A1b. These data established D2 as the recommended surgical approach, provided it is performed with spleen-preserving technique in high-volume centers [17]A1b.
Locoregional Recurrence
Locoregional recurrence is defined as disease at the anastomotic site, duodenal stump, tumor bed, remnant stomach, or regional lymph nodes within the radiation field [10]A1b. The ARTIST trial demonstrated that adding 45 Gy radiotherapy to plus (XP) after D2 dissection did not significantly reduce recurrence overall, but in the subgroup of patients with positive lymph nodes, radiotherapy improved disease-free survival (95% CI 0.47-1.00) [12]A1b. The subsequent ARTIST 2 trial in node-positive, D2-resected patients found that adjuvant SOX (S-1 plus ) improved 3-year DFS to 74.3% versus 64.8% with S-1 alone (, P=0.042), while adding radiotherapy to SOX provided no additional benefit [2]A1b. Thus, locoregional recurrence risk is most effectively reduced by adequate lymphadenectomy plus systemic chemotherapy, reserving radiotherapy for patients with node-positive disease after less-than-optimal dissection.
Distant Metastatic Patterns
Distant metastases include lymph node recurrence outside the radiation field, liver metastases, and other extra-abdominal sites [10]A1b. The REGATTA trial addressed a key clinical question: whether plus chemotherapy improves survival over chemotherapy alone in patients with a single non-curable factor (liver H1, peritoneum P1, or para-aortic lymph node 16a1/b2). The trial was stopped early for futility, median OS was 16.6 months with chemotherapy alone versus 14.3 months with gastrectomy plus chemotherapy (HR 1.09, 95% CI 0.78-1.52) [18]A1b. This finding establishes that surgical resection of the primary tumor does not improve survival once distant metastases are present, and the pattern of recurrence dictates that systemic therapy is the primary management.
Peritoneal Recurrence
Peritoneal metastases are the most common distant pattern and carry a particularly poor prognosis. The GASTRIPEC-I trial evaluated cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with synchronous peritoneal metastases. Median OS was identical (14.9 months in both arms), but PFS was significantly longer with HIPEC (7.1 vs 3.5 months) and distant metastasis-free survival improved (10.2 vs 9.2 months) [7]A1b. The PHOENIX-GC trial compared intraperitoneal plus intravenous with S-1 (IP) versus S-1 plus cisplatin (SP) in patients with peritoneal metastasis. Median OS was 17.7 months with IP versus 15.2 months with SP (HR 0.72, 95% CI 0.49-1.04), and after adjusting for baseline , the HR was 0.59 (95% CI 0.39-0.87) [8]A1b. These trials suggest that patients with peritoneal-limited recurrence may benefit from a regional approach, but the pattern of disease must be confirmed before choosing therapy.
Pearl: The pattern of recurrence, locoregional, distant, or peritoneal, is not random; it is strongly influenced by the quality of initial surgery (D1 vs D2), nodal status, and tumor biology. Identifying the pattern with cross-sectional imaging and, when indicated, diagnostic laparoscopy is the essential first step before selecting any salvage therapy, because the failure (where surgery or radiotherapy may be considered) differs fundamentally from that of disseminated disease (where systemic therapy remains the backbone).
| Recurrence Type | D1 (n=380) | D2 (n=331) | Difference |
|---|---|---|---|
| Local recurrence | 22% (82) | 12% (40) | 10% absolute reduction |
| Regional recurrence | 19% (73) | 13% (43) | 6% absolute reduction |
| Gastric-cancer-related death | 48% (182) | 37% (123) | 11% absolute reduction |
Data from Songun I, et al. Lancet Oncol 2010 [17]A1b.
Workup of Suspected Recurrence
- ▸Eight consensus symptoms (dysphagia to solids/liquids, vomiting, abdominal/chest pain, regurgitation, weight loss, hoarseness) should trigger investigation for recurrence.
- ▸68Ga-FAPI PET/CT detects recurrence missed by CT and changes management in ~18% of patients; CT-ECV ≥56.9% predicts high-risk recurrence.
- ▸ctDNA positivity precedes radiographic recurrence in >80% of patients; combining ctDNA with tumour markers improves detection and response assessment.
The workup of suspected recurrence integrates clinical assessment, biomarker surveillance, imaging, and-where feasible-biopsy confirmation. A standardized surveillance strategy after curative resection has not been established, but risk-adapted approaches improve cost-effectiveness.
Clinical Suspicion and Surveillance
A modified Delphi consensus identified eight symptoms that should trigger investigation for recurrent esophagogastric cancer: dysphagia to solid food, dysphagia to liquids, vomiting, abdominal pain, chest pain, regurgitation of foods, unexpected weight loss, and progressive hoarseness [25]A1b. For asymptomatic patients with pathological stage (pStage) II/III disease, surveillance intensity should be stratified: a risk-based individualized strategy is most cost-effective for pStage II (ICER $490/QALY), whereas the NCCN guideline (more intensive schedule) is preferred for pStage III (ICER $983/QALY) [24]A1b.
Imaging Modalities for Recurrence Detection
Contrast-enhanced CT (CECT) is the standard initial modality. Beyond morphological assessment, CT-derived biomarkers enhance risk prediction. The CT-derived extracellular volume fraction (CT-ECV) quantifies the tumour stroma; a threshold of ≥56.9% predicts postoperative recurrence in pStage II-III with sensitivity 82.1% and specificity 61.9% (AUC 0.71) [37]B3b. CT-based radiomic models, such as the Radiomics-Clinical Integrated Risk Stratification Assessment (RSA) model, predict early recurrence (within 2 years) with AUC values of 0.870-0.873 in external validation cohorts [27]B2b. A multimodal RSA model integrating clinical, radiomic, and pathomic features achieves AUCs of 0.903 (training) and 0.884-0.889 (external validation) [28]B2b.
68Ga-FAPI PET/CT offers superior detection of recurrent disease compared with CT alone. In a cohort of 28 patients evaluated for postoperative recurrence, FAPI PET/CT identified recurrence in 7 additional patients and led to a management change in 17.9% of all patients (19 major, 1 minor) [40]C4. A meta-analysis of FAP-targeted PET reported pooled detection rates of 95% for primary tumour and 97% for distant metastases, with pooled sensitivity 74% and specificity 89% for regional lymph node metastases [26]B2a. Among patients with recurrent gastric cancer undergoing chemoimmunotherapy, [18F]ALF-NOTA-FAPI-04 PET/CT parameters independently predict outcomes: total lesion FAP expression (TLF) ≥188.88 SUVbw·cm³ was associated with worse progression-free survival (HR 7.29), and FAPI-avid tumour volume (FTV) ≥44.17 cm³ with worse overall survival (HR 5.16) [32]C4.
Deep learning models applied to preoperative CT can predict specific recurrence patterns. A multitask model predicted peritoneal recurrence with AUC 0.843-0.857 in external validation [29]B2b. A CT-based radiomics model for T4 tumours identified patients at high risk of peritoneal recurrence (AUC 0.820) who may benefit from prophylactic hyperthermic intraperitoneal chemotherapy (HR 0.490) [35]B3b.
Biomarkers and Molecular Profiling
Circulating tumour DNA (ctDNA) is a powerful adjunct to imaging. In a cohort of 36 patients with stage I-III disease who recurred, 80.65% were ctDNA-positive within 90 days before radiographic recurrence [33]C4. ctDNA dynamics also predict treatment response: patients who cleared ctDNA after neoadjuvant chemotherapy had favourable outcomes, and combining ctDNA with tumour markers (CEA, CA19-9, CA72-4, CA125, CA242) increased the overall positive rate to 94.9% and improved agreement with pathological response to 83.8% [39]B3b.
For all patients with confirmed recurrence, tissue biopsy (or repeat biopsy of accessible lesions) is recommended to reassess:
- HER2 status (may change from primary tumour)
- PD-L1 combined positive score (CPS)
- Microsatellite instability (MSI) or mismatch repair deficiency deruxtecan (T-DXd) is an option for HER2-positive advanced or recurrent gastric cancer; real-world surveillance found any-grade ILD in 9.6% (grade ≥3 in 2.8%, grade 5 in 1.2%), with median onset 2.9 months, mandating vigilant monitoring [21]B3b.
Pearl: When investigating suspected recurrence, a normal CT does not rule out disease; consider 68Ga-FAPI PET/CT for its superior sensitivity, and always obtain tissue for re-biopsy to guide biomarker-driven therapy, as HER2 and PD-L1 status can change between primary and recurrent disease.
| Modality | AUC / Detection Rate | Key Threshold | Clinical Utility |
|---|---|---|---|
| CT-ECV [37]B3b | AUC 0.71 | ≥56.9% | Independent predictor of DFS (HR 5.93) in pStage II-III |
| CT radiomics (RSA model) [27]B2b | AUC 0.870-0.873 (external) | Risk score dichotomized | Predicts early recurrence within 2 years |
| Multimodal RSA (CT + pathology) [28]B2b | AUC 0.903 (training), 0.884-0.889 (external) | Score ≥0.19 identifies chemotherapy benefit | Adds significant net reclassification improvement |
| 68Ga-FAPI PET/CT [40]C4 | Changed management in 17.9% | N/A | Detects additional recurrences, influences treatment |
| FAPI PET/CT (meta-analysis) [26]B2a | Sensitivity 74%, Specificity 89% (LN) | N/A | Superior to FDG for LN and distant metastases |
| [18F]FAPI-04 PET/CT [32]C4 | TLF AUC 0.80 for durable clinical benefit | TLF ≥188.88, FTV ≥44.17 cm³ | Independent predictor of PFS and OS |
| Deep learning (peritoneal recurrence) [29]B2b | AUC 0.843-0.857 | N/A | Predicts peritoneal recurrence; guides HIPEC decisions |
| Symptom | Consensus Agreement |
|---|---|
| Dysphagia to solid food | ≥75% |
| Dysphagia to liquids | ≥75% |
| Vomiting | ≥75% |
| Abdominal pain | ≥75% |
| Chest pain | ≥75% |
| Regurgitation of foods | ≥75% |
| Unexpected weight loss | ≥75% |
| Progressive hoarseness of voice | ≥75% |
Local-Regional Recurrence
- ▸Isolated locoregional recurrence after curative resection is rare (4%); most recurrences are distant.
- ▸EMR-HA is superior to thermal ablation for residual positive margins after ESD, with a recurrence rate of 11.5%.
- ▸SBRT for isolated para-aortic lymph node recurrence achieved 3-year OS of 43% with no severe toxicity.
Once a locoregional recurrence is confirmed by the workup described above, management decisions depend on the pattern of relapse, prior treatments, and the patient's functional status. Isolated locoregional recurrence is uncommon, occurring in only 4% of recurrences after curative resection in one series [41]C4. The remaining 86% of recurrences involved distant sites, and 10% had both [41]C4. For the minority with truly isolated locoregional disease, salvage options include endoscopic resection, surgery, and ablative radiotherapy.
Patterns of Local-Regional Recurrence
After non-curative endoscopic submucosal dissection (ESD) for early , the most common recurrence pattern is distant metastasis, seen in 60% of patients who recurred without additional treatment [42]C4. Intragastric relapse occurred in 12% and regional lymph node metastasis in 28% [42]C4. The median time from ESD to recurrence was 14.8 months in a mixed cohort of gastroesophageal adenocarcinomas [41]C4.
Salvage Surgery
Salvage surgery for locoregional recurrence after non-curative ESD carries limited survival benefit. Among 27 patients with recurrence, 7 underwent salvage surgery; median survival after recurrence was 5 months for all patients and 7 months for those who had surgery [42]C4. Only one patient survived without recurrence at 31 months; the others died of disease [42]C4. For patients with recurrence after , colon interposition (salvage coloplasty) is an option with 5-year survival of 38% but high morbidity (86%) and 14% mortality [48]D5.
Endoscopic Management
For residual positive lateral margins (≤1 cm) after ESD, a sequential endoscopic approach offers disease control. Hybrid endoscopic mucosal resection-hot avulsion (EMR-HA) resulted in a lower recurrence rate of 11.5% (3/26) compared with hot avulsion (44%, 11/25) and argon plasma coagulation (36.6%, 15/41) over a median follow-up of 63 months [44]C4. Among patients who recurred, re-ESD achieved complete resection in 84.6% (22/26) with a median disease-free survival of 34.5 months [44]C4.
| Endoscopic Technique | Recurrence Rate | Median Recurrence Interval |
|---|---|---|
| EMR-HA | 11.5% (3/26) | Not reported |
| Hot avulsion | 44% (11/25) | 20 months |
| Argon plasma coagulation | 36.6% (15/41) | 18 months |
Data from Zhang et al. [44]C4; median recurrence interval for thermal ablation cohort significantly shorter than negative lateral margin cohort (32 months, P < 0.05).
( )
SBRT is a salvage option for isolated para-aortic lymph node recurrence after curative resection. In a small series of 7 patients, SBRT doses of 45-51 Gy (median 48 Gy) in 3 fractions produced complete response in 5 of 7 patients; 3-year overall survival was 43% and 3-year progression-free survival 29% [50]C4. No severe complications were reported [50]C4.
Systemic Therapy
For locoregional recurrence that is not amenable to local therapy, second-line chemotherapy prolongs survival compared with best supportive care alone (HR 0.64, 95% CI 0.52-0.79; NNT not calculable from reported data) [1]B2a. Third-line (75 mg/m² every 3 weeks) yields a median overall survival of 4.7 months (95% CI 3.20-6.20) with grade 3-4 neutropenia in 58% [46]B2b. Prognostic factors for benefit from third-line therapy include performance status 0-1, serum albumin ≥4 mg/dL, favorable histology, and progression-free survival ≥2.7 months after second-line [49]D5. Detailed systemic therapy is discussed in the Distant Metastatic Disease section.
Pearl: For isolated locoregional recurrence, SBRT or salvage surgery can be considered, but outcomes are modest; the majority of patients eventually develop distant disease, so systemic therapy remains a cornerstone of management.
Distant Metastatic Disease
- ▸Biomarker retesting (HER2, MSI, PD-L1 CPS) at recurrence is essential to guide first-line therapy; immunotherapy-chemotherapy improves OS in HER2-negative disease (HR 0.79) [57].
- ▸Second-line therapy choice depends on platinum-free interval; paclitaxel and irinotecan are equivalent options (WJOG 4007) [11].
- ▸Intraperitoneal paclitaxel plus S-1 improves OS in peritoneal metastases (DRAGON-01; HR 0.67) [52]; HIPEC adds PFS benefit after complete cytoreduction [7].
For patients with distant metastatic , the treatment pathway is determined by biomarker status, prior platinum exposure, and the pattern of metastatic spread. Whereas local-regional recurrence may be approached with locoregional therapy, distant disease mandates systemic therapy as the backbone, with locoregional strategies reserved for selected presentations.
First-Line Therapy
All patients should undergo retesting of tumor tissue for HER2, MSI, and PD-L1 combined positive score (CPS) at the time of recurrence, as expression can change during disease evolution. For HER2-negative disease, the standard of care is a platinum-fluoropyrimidine doublet (e.g., plus or plus ) combined with an immune checkpoint inhibitor. A network meta-analysis of eight randomized trials (n = 7619) demonstrated that immunotherapy-chemotherapy significantly improved overall survival (HR 0.79, 95% CI 0.74-0.84), progression-free survival (HR 0.72, 0.68-0.77), and objective response rate (RR 1.61, 1.45-1.80) compared with chemotherapy alone in HER2-negative advanced disease, though with a higher incidence of grade ≥3 adverse events (RR 1.18, 1.13-1.23) [57]A1a. The benefit was greatest in patients with PD-L1 CPS ≥10, but clinically meaningful improvements were also seen at CPS ≥1 and ≥5 [57]A1a. For patients with PD-L1 CPS ≥5, the evidence supports a first-line regimen containing or . For HER2-positive disease, is added to the chemotherapy backbone (based on the ToGA trial, not included in this evidence set).
Second-Line Therapy
After progression on a platinum-based first-line regimen, the choice of second-line therapy depends on the platinum-free interval. For patients with a short interval (<6 months), non-platinum agents are preferred. The WJOG 4007 phase III trial compared weekly (80 mg/m² on days 1, 8, 15 every 4 weeks) with biweekly (150 mg/m² on days 1 and 15 every 4 weeks) in 219 eligible patients with advanced gastric cancer refractory to fluoropyrimidine plus platinum. Median OS was 9.5 months with paclitaxel vs 8.4 months with irinotecan (HR 1.13, 95% CI 0.86-1.49); median PFS was 3.6 vs 2.3 months (HR 1.14, 0.88-1.49) [11]A1b. Both are reasonable options. Paclitaxel plus is a standard second-line regimen (RAINBOW trial, not in this evidence set). For patients with a longer platinum-free interval, re-challenge with a platinum-based regimen may be considered.
Third-Line Therapy
In the refractory setting, (160 mg orally once daily on days 1-21 of a 28-day cycle) prolonged PFS compared with placebo (2.6 vs 0.9 months; HR 0.40, 95% CI 0.28-0.59; P < 0.001) in the phase II INTEGRATE trial, with a trend toward improved OS (5.8 vs 4.5 months; HR 0.74) [51]B2b.
Peritoneal Metastases
Peritoneal dissemination represents a distinct clinical challenge. The DRAGON-01 phase III trial (n = 222) randomly assigned patients with laparoscopically confirmed peritoneal metastasis to intraperitoneal and intravenous paclitaxel plus S-1 (IP group: paclitaxel 50 mg/m² IV + 20 mg/m² IP on days 1 and 8, S-1 80 mg/m² daily on days 1-14, 21-day cycle) or intravenous paclitaxel plus S-1 (PS group). Median OS was 19.4 months (95% CI 17.1-22.9) in the IP group vs 13.9 months (95% CI 10.3-16.1) in the PS group (HR 0.67, 95% CI 0.50-0.90; P = 0.01); median PFS was 11.2 vs 7.2 months (HR 0.72, 0.54-0.96) [52]A1b. Grade 3-4 adverse events occurred in 38.5% vs 41.9%, with no treatment-related deaths. The PHOENIX-GC trial reported a consistent but not statistically significant OS benefit (HR 0.72, 0.49-1.04; adjusted for : HR 0.59, 0.39-0.87) [8]A1b. The GASTRIPEC-I trial of cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) showed no OS benefit in the full analysis set (median OS 14.9 months in both arms), but PFS was significantly longer with HIPEC (7.1 vs 3.5 months) and a prespecified subgroup of patients achieving complete cytoreduction (CCR0) had improved OS [7]A1b. A meta-analysis of nine RCTs (n = 1021) confirmed that HIPEC reduced peritoneal metastasis (OR 0.24, 95% CI 0.16-0.35) and distant metastasis (OR 0.45, 0.28-0.71) and improved 3-year survival (OR 1.48, 1.01-2.17) without increasing complications [54]A1a. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a palliative option for refractory peritoneal metastases, with reported objective response rates of 50-91% in gastric cancer and median survival of 8-15 months [61]D5.
in Metastatic Disease
The REGATTA phase III trial demonstrated that gastrectomy followed by chemotherapy does not improve survival compared with chemotherapy alone in patients with advanced gastric cancer and a single non-curable factor (liver, peritoneum, or para-aortic nodes). Median OS was 16.6 months with chemotherapy alone vs 14.3 months with gastrectomy plus chemotherapy (HR 1.09, 95% CI 0.78-1.52; P = 0.70) [18]A1b. Gastrectomy is therefore not justified for palliation in this setting.
| Trial | Population | Regimen | OS (months) | HR (95% CI) | NNT/NNH |
|---|---|---|---|---|---|
| Network meta-analysis [57]A1a | HER2-negative, first-line | Immuno-chemotherapy vs chemo | Not reported | 0.79 (0.74-0.84) | NNT not calculable from reported data |
| WJOG 4007 [11]A1b | Second-line, post-platinum | Paclitaxel vs irinotecan | 9.5 vs 8.4 | 1.13 (0.86-1.49) | Not significant |
| INTEGRATE [51]B2b | Refractory, third-line | Regorafenib vs placebo | 5.8 vs 4.5 | 0.74 (0.49-1.11)* | NNT not calculable for PFS |
| DRAGON-01 [52]A1b | Peritoneal metastasis, first-line | IP paclitaxel + S-1 vs IV paclitaxel + S-1 | 19.4 vs 13.9 | 0.67 (0.50-0.90) | NNT not calculable from reported data |
| GASTRIPEC-I [7]A1b | Peritoneal metastasis, CRS ± HIPEC | CRS + HIPEC vs CRS alone | 14.9 vs 14.9 | 0.72 (0.39-1.32) | Not significant for OS |
| REGATTA [18]A1b | Single non-curable factor | Gastrectomy + chemo vs chemo alone | 14.3 vs 16.6 | 1.09 (0.78-1.52) | Not significant |
| *OS HR is for trend, not significant. |
Pearl: For patients with distant metastatic gastric cancer, first-line therapy is guided by biomarker retesting (HER2, PD-L1, MSI); isolated peritoneal metastases are an indication for intraperitoneal paclitaxel (HR 0.67 for OS [52]A1b), while gastrectomy does not improve survival and should be avoided outside of clinical trials [18]A1b.
Oligometastatic Disease
- ▸Oligometastatic disease is defined as ≤3 metastases in a single organ or one extra-regional lymph node station; the OMEC consensus provides a disease-free interval-based algorithm for treatment sequencing.
- ▸Local treatment (SBRT, metastasectomy, or proton beam therapy) combined with systemic therapy improves overall survival compared with systemic therapy alone (HR 0.42-0.52).
- ▸Peritoneal oligometastasis is defined by PCI ≤6; selected patients achieve 5-year survival of 30-50% with CRS and HIPEC.
While most patients with distant metastases receive systemic therapy alone, a subset with limited metastatic burden, termed oligometastatic disease (OMD), may benefit from the addition of metastasis-directed local therapy. The European OMEC consensus defines OMD in esophagogastric cancer as ≤3 metastases confined to a single organ or involvement of one extra-regional lymph node station [66]A1c[68]B2a. Peritoneal oligometastasis is considered separately, with a peritoneal cancer index (PCI) threshold of ≤6 serving as a pragmatic cutoff [81]D5.
Definition and Patient Selection
The OMEC project further stratifies by disease-free interval (DFI): for synchronous OMD or metachronous OMD with DFI ≤2 years, recommended treatment begins with systemic therapy followed by restaging to assess suitability for local therapy; for metachronous OMD with DFI >2 years, upfront local treatment is also an option [66]A1c[68]B2a. A nationwide Dutch cohort of 594 patients reported that local treatment ( ] or metastasectomy) alone yielded a median overall survival (OS) of 16.0 months, local treatment plus systemic therapy 22.7 months, and systemic therapy alone 8.5 months; both local-treatment strategies were independently associated with improved OS (HR 0.52, 95% CI 0.31-0.90 and HR 0.42, 95% CI 0.22-0.82) [65]A1b.
Local Treatment Modalities
SBRT is increasingly used for liver and lung oligometastases. Japanese nationwide data on for liver metastases from esophagogastric cancer reported 1-, 2-, and 3-year OS rates of 75%, 51.8%, and 45.3%, respectively, with a 3-year cumulative local recurrence rate of only 6% and no Grade ≥3 adverse events [78]C4. Metastasectomy for synchronous liver metastases produced a median OS of 21 months (IQR 9-36) and 5-year survival of 30% in a multicenter cohort; patients with a solitary liver metastasis had a median OS of 34 months [73]C4. For retroperitoneal lymph node metastases, the IKF-575/RENAISSANCE phase III trial found that only patients with isolated retroperitoneal node metastases derived a survival benefit from adding local therapy [70]B2b.
Systemic Therapy Integration
Conversion surgery after induction chemotherapy is a key strategy. The Neo-REGATTA study showed that radical resection after , , and S-1 (DOS) chemotherapy significantly prolonged progression-free and overall survival compared with chemotherapy alone [75]C4. Following curative resection of synchronous oligometastases, postoperative chemotherapy (S-1 or S-1 plus ) improved median OS to 35.2 months versus 11.1 months without it (HR 3.56, 95% CI 1.74-7.30) [74]C4. The AIO-FLOT3 trial prospectively confirmed favorable survival with multimodal treatment including surgery and chemotherapy [69]B2b.
Peritoneal Oligometastasis
Peritoneal dissemination historically carries a poor prognosis, but selected patients with PCI ≤6 may achieve long-term survival with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), with 5-year survival rates of 30-50% in expert centers [81]D5. The OMEC consensus classifies peritoneal metastases as polymetastatic by default, yet the latest evidence supports a PCI-based definition of oligometastatic peritoneal disease [81]D5[83]D5.
Pearl: The selection of oligometastatic patients for local therapy requires a strict definition (≤3 metastases in one organ), a disease-free interval >2 years for metachronous disease, and multidisciplinary evaluation to confirm disease stability after systemic therapy, only then does metastasis-directed treatment offer a survival advantage over systemic therapy alone.
| Modality | Typical Indication | Key Outcomes | Reference |
|---|---|---|---|
| SBRT | Liver, lung, lymph node (≤3 lesions) | Median OS 16-22.7 mo; 3-yr local control ~94% | [65]A1b[78]C4 |
| Proton beam therapy | Liver oligometastases (≤3 lesions) | 3-yr OS 45.3%; no Grade ≥3 AEs | [78]C4 |
| Metastasectomy | Solitary liver metastasis, resectable lymph node | Median OS 21-34 mo; 5-yr OS 30% | [73]C4 |
| CRS + HIPEC | Peritoneal oligometastasis (PCI ≤6) | 5-yr OS 30-50% | [81]D5 |
Prognosis of Recurrent Disease
- ▸Second-line chemotherapy reduces the risk of death by 36% (HR 0.64, 95% CI 0.52-0.79) versus best supportive care [1].
- ▸Median overall survival falls from 9-10 months in second-line to 4-5 months in third-line therapy [4,85,89,91].
- ▸The GC-RiskAssigner seven-gene signature stratifies post-resection prognosis (HR 5.1 for high- vs low-risk) [3].
For patients whose disease recurs after initial therapy and is not amenable to curative-intent treatment, the prognosis is poor, with median survival measured in months. However, sequential systemic therapy can meaningfully prolong survival and improve quality of life.
Natural History and Survival by Line of Therapy
Without active treatment, survival is short. The landmark meta-analysis of salvage chemotherapy demonstrated a 36% reduction in the risk of death (HR 0.64, 95% CI 0.52-0.79) with second-line chemotherapy compared to best supportive care [1]B2a. In the second-line setting, the DREAM trial of oral versus intravenous reported median overall survival (OS) of 9.7 versus 8.9 months [85]A1b. For patients receiving third-line therapy, outcomes are more limited: the JAVELIN Gastric 300 trial of avelumab versus physician's choice of chemotherapy showed median OS of 4.6 versus 5.0 months [4]A1b. The GRANITE-1 trial of everolimus versus placebo yielded median OS of 5.4 versus 4.3 months [89]B2b. The VEGFR-2 inhibitor apatinib improved median OS from 2.5 months with placebo to 4.83 months (850 mg once daily) in heavily pretreated patients [91]B2b. The combination of olaparib plus paclitaxel, in a selected population, achieved median OS of 13.1 months versus 8.3 months with paclitaxel alone (HR 0.56) [90]B2b.
Prognostic Factors
Several factors independently predict survival after recurrence. The table below summarizes the best-validated prognostic variables.
| Factor | Favorable Prognosis | Unfavorable Prognosis | Evidence |
|---|---|---|---|
| Performance status ( ) | 0-1 | ≥2 | Clinical consensus |
| Disease-free interval after primary therapy | >12 months | <6 months | Clinical consensus |
| Number of metastatic sites | Single site / oligometastatic | Multiple sites | Clinical consensus |
| GC-RiskAssigner seven-gene signature* | Low-risk: median OS 80.9 months (95% CI 43.0-NA) | High-risk: median OS 10.2 months (95% CI 6.5-13.2); HR 5.1 (95% CI 2.8-9.2) | [3]A1b |
| First-degree family history of (stage III/IV) | Present: HR 0.47 (95% CI 0.26-0.84) for OS | Absent | [16]B3b |
| ATM protein expression (low) | Improved OS with olaparib/paclitaxel (HR 0.35) | Normal/high ATM | [90]B2b |
| CLDN18.2 expression ≥70% (moderate-strong) | Monotherapy ORR 14% (4/29) | Lower expression | [92]B2b |
*The GC-RiskAssigner signature was developed in the MAGIC trial for patients who received perioperative chemotherapy; it stratifies risk after curative resection [3]A1b.
Prognostic Scores and Gene Signatures
A nomogram for early gastric cancer recurrence after curative resection, externally validated in a cohort of 1058 patients, achieved a concordance index of 0.82 (95% CI 0.59-1.00) and showed good calibration for 1- and 2-year survival [87]C4. The GC-RiskAssigner seven-gene signature (CDH1, ELOVL5, EGFR, PIP5K1B, FGF1, CD44v8.10, TBCEL) identified high-risk patients with a median OS of 10.2 months, compared with 80.9 months for low-risk patients in the MAGIC trial (HR 5.1, 95% CI 2.8-9.2) [3]A1b. This signature retained independent prognostic value after controlling for lymph node status [3]A1b.
Pearl: The most powerful modifiable determinant of prognosis in recurrent disease is the delivery of second-line chemotherapy, which reduces the risk of death by 36% (HR 0.64, 95% CI 0.52-0.79) compared with best supportive care; however, long-term survival remains rare and is best predicted by performance status, disease-free interval, and molecular markers such as the GC-RiskAssigner signature and ATM status.
Related Pages
Part of the Gastric Cancer family. Cross-cutting management is split across dedicated child pages:
- , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
- Gastric Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
- Gastric Cancer Radiation Management , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
- , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
- Gastric Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
- Gastric Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
Pearl: Use these links to hop between management modalities; the parent Gastric Cancer page carries diagnosis + staging that informs every decision here.
References
- [1]
Kim HS, Kim HJ, Kim SY et al.. “Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23942775 ↗
L2SR_COHORTCited in: Patterns of Recurrence, Local-Regional Recurrence, Prognosis of Recurrent Disease - [2]
Park SH, Lim DH, Sohn TS et al.. “A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33278599 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [3]
Smyth EC, Nyamundanda G, Cunningham D et al.. “A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30481267 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [4]
Bang YJ, Ruiz EY, Van Cutsem E et al.. “Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30052729 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [5]
Jeung HC, Moon YW, Rha SY et al.. “Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 18029971 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [6]
Ryu MH, Baba E, Lee KH et al.. “Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26216386 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [7]
Rau B, Lang H, Koenigsrainer A et al.. “Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37906724 ↗
L1RCTCited in: Patterns of Recurrence, Distant Metastatic Disease - [8]
Ishigami H, Fujiwara Y, Fukushima R et al.. “Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29746229 ↗
L1RCTCited in: Patterns of Recurrence, Distant Metastatic Disease - [9]
Kim YW, Min JS, Yoon HM et al.. “Laparoscopic Sentinel Node Navigation Surgery for Stomach Preservation in Patients With Early Gastric Cancer: A Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35324317 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [10]
Fuchs CS, Niedzwiecki D, Mamon HJ et al.. “Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28976791 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [11]
Hironaka S, Ueda S, Yasui H et al.. “Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24190112 ↗
L1RCTCited in: Patterns of Recurrence, Distant Metastatic Disease - [12]
Lee J, Lim DH, Kim S et al.. “Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 22184384 ↗
L1RCTCited in: Patterns of Recurrence, Distant Metastatic Disease, Prognosis of Recurrent Disease - [13]
Lordick F, Mauer ME, Stocker G et al.. “Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39542422 ↗
L2RCT_PHASE2Cited in: Patterns of Recurrence - [14]
Van Cutsem E, Boni C, Tabernero J et al.. “Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25416687 ↗
L2RCT_PHASE2Cited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [15]
Veen LM, Skrabanja TLP, Derks S et al.. “The role of transforming growth factor β in upper gastrointestinal cancers: A systematic review.” Cancer treatment reviews (2021). PMID: 34536730 ↗
L2SR_COHORTCited in: Patterns of Recurrence - [16]
Han MA, Oh MG, Choi IJ et al.. “Association of family history with cancer recurrence and survival in patients with gastric cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22271486 ↗
L3COHORTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [17]
Songun I, Putter H, Kranenbarg EM et al.. “Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.” The Lancet. Oncology (2010). PMID: 20409751 ↗
L1RCTCited in: Patterns of Recurrence - [18]
Fujitani K, Yang HK, Mizusawa J et al.. “Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.” The Lancet. Oncology (2016). PMID: 26822397 ↗
L1RCTCited in: Patterns of Recurrence, Distant Metastatic Disease - [19]
Wu CW, Hsiung CA, Lo SS et al.. “Nodal dissection for patients with gastric cancer: a randomised controlled trial.” The Lancet. Oncology (2006). PMID: 16574546 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [20]
Tsuburaya A, Yoshida K, Kobayashi M et al.. “Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.” The Lancet. Oncology (2014). PMID: 24954805 ↗
L1RCTCited in: Patterns of Recurrence, Distant Metastatic Disease - [21]
Kawakami H, Uchino K, Hashimoto W et al.. “Real-world evaluation of interstitial lung disease/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan.” ESMO open (2025). PMID: 41349223 ↗
L3COHORTCited in: Workup of Suspected Recurrence - [22]
Yoshida K, Ninomiya M, Takakura N et al.. “Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16740764 ↗
L2NON_RANDOMIZED_TRIALCited in: Workup of Suspected Recurrence - [23]
Zhong Q, Wu D, Liu ZY et al.. “Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial.” BMC medicine (2025). PMID: 40859341 ↗
L1RCTCited in: Workup of Suspected Recurrence - [24]
Wu D, Lu J, Lin J et al.. “An international multi-institution real-world study of the optimal surveillance frequency for stage II/III gastric cancer: the more, the better?” International journal of surgery (London, England) (2023). PMID: 37800589 ↗
L1RCTCited in: Workup of Suspected Recurrence - [25]
Chidambaram S, Patel NM, Sounderajah V et al.. “Identifying a core symptom set triggering radiological and endoscopic investigations for suspected recurrent esophago-gastric cancer: a modified Delphi consensus process.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2022). PMID: 35858213 ↗
L1RCTCited in: Workup of Suspected Recurrence - [26]
Rizzo A, Racca M, Garrou F et al.. “Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.” International journal of molecular sciences (2023). PMID: 37373285 ↗
L2SR_COHORTCited in: Workup of Suspected Recurrence - [27]
Ding P, Chen S, Guo H et al.. “Radiomics-based ensemble model predicts postoperative recurrence of gastric cancer.” BMC medicine (2025). PMID: 41291636 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence - [28]
Ding P, Yang J, Chen S et al.. “Interpretable Multimodal Fusion Model Enhances Postoperative Recurrence Prediction in Gastric Cancer.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2025). PMID: 40944934 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence - [29]
Jiang Y, Zhang Z, Yuan Q et al.. “Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study.” The Lancet. Digital health (2022). PMID: 35461691 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence - [30]
Yan J, Qi Z, Zhang R. “A nomogram integrating p53 and Ki-67 expression for predicting recurrence risk in postoperative early gastric cancer.” World journal of surgical oncology (2026). PMID: 42157210 ↗
L3RETROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence - [31]
Wang J, Liu M, Fan B et al.. “Long-term and second recurrence following curative ESD for synchronous multiple early gastric neoplasia: a single-center cohort study.” Surgical endoscopy (2026). PMID: 41758371 ↗
L3RETROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence - [32]
He H, Xie Y, Jiang C et al.. “Prognostic Significance of Pretreatment [¹⁸F]ALF-NOTA-FAPI-04 PET/CT in Patients With Recurrent Gastric Cancer Undergoing Combined PD-1 Inhibitor and Chemotherapy.” Korean journal of radiology (2026). PMID: 41735817 ↗
L4RETROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence - [33]
Mehta R, Rivero-Hinojosa S, Dayyani F et al.. “Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers.” Cancer (2026). PMID: 41485117 ↗
L4RETROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence - [34]
Kim C, Lee HS, Na HY et al.. “Prognostic value of signet-ring cell carcinoma proportion in undifferentiated gastric cancer: Implications for endoscopic treatment decisions.” World journal of gastroenterology (2025). PMID: 40904880 ↗
L3COHORTCited in: Workup of Suspected Recurrence - [35]
Jiang Z, Yang M, Jiang S et al.. “Predicting peritoneal recurrence and hyperthermic intraperitoneal chemotherapy benefits in T4 gastric cancer patients via contrast-enhanced CT radiomics.” European journal of radiology (2025). PMID: 40738014 ↗
L3RETROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence - [36]
Cong R, Ming J, Xu R et al.. “Development and validation of a preoperative CT-based risk score integrating morphological and body composition parameters to predict recurrence-free survival in gastric cancer patients following curative surgery.” European journal of radiology (2025). PMID: 40684710 ↗
L3RETROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence - [37]
Nishimuta Y, Tsurumaru D, Fujita N et al.. “CT-derived extracellular volume fraction as a predictive marker for postoperative recurrence in pStage II-III gastric cancer.” European radiology (2025). PMID: 40531317 ↗
L3COHORTCited in: Workup of Suspected Recurrence - [38]
Xu M, Wang L, Sun S et al.. “A nomogram model based on CT-assessed body composition parameters for predicting postoperative recurrence in advanced gastric cancer.” Abdominal radiology (New York) (2025). PMID: 40526138 ↗
L3COHORTCited in: Workup of Suspected Recurrence - [39]
Zhu H, Jia Y, Pang F et al.. “Utilizing Combined Circulating Tumor DNA and Tumor Markers to Evaluate Neoadjuvant Therapy Response and Predict Recurrence in Patients with Locally Advanced Gastric Cancer.” Annals of surgical oncology (2025). PMID: 40459666 ↗
L3COHORTCited in: Workup of Suspected Recurrence - [40]
Zhang S, Su M, Li Q et al.. “Impact of 68Ga-FAPI positron emission tomography/computed tomography on staging and tumor management in patients with gastric cancer.” Journal of cancer research and clinical oncology (2025). PMID: 39815070 ↗
L4COHORTCited in: Workup of Suspected Recurrence - [41]
Jiang DM, Suzuki C, Espin-Garcia O et al.. “Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma.” Cancer medicine (2020). PMID: 32130793 ↗
L4PROSPECTIVE_COHORTCited in: Local-Regional Recurrence - [42]
Takizawa K, Hatta W, Gotoda T et al.. “Recurrence Patterns and Outcomes of Salvage Surgery in Cases of Non-Curative Endoscopic Submucosal Dissection without Additional Radical Surgery for Early Gastric Cancer.” Digestion (2018). PMID: 30554228 ↗
L4COHORTCited in: Local-Regional Recurrence - [43]
Ando T, Hosokawa A, Sakumura M et al.. “Factors, Including Clinical Trial Eligibility, Associated with Induction of Third-Line Treatment for Advanced Gastric Cancer.” Oncology (2022). PMID: 36103845 ↗
L3COHORTCited in: Local-Regional Recurrence - [44]
Zhang L, An N, Zheng X et al.. “Comparative clinical efficacy of hybrid EMR-hot avulsion versus thermal ablation for post-ESD residual margins (≤ 1 cm) in early gastric cancer: a preliminary study.” BMC surgery (2025). PMID: 41168768 ↗
L4RETROSPECTIVE_COHORTCited in: Local-Regional Recurrence - [45]
Lim JY, Cho JY, Paik YH et al.. “Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.” Oncology (2008). PMID: 18332648 ↗
L2NON_RANDOMIZED_TRIALCited in: Local-Regional Recurrence - [46]
Lee JH, Kim SH, Oh SY et al.. “Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer.” The Korean journal of internal medicine (2013). PMID: 23682225 ↗
L2NON_RANDOMIZED_TRIALCited in: Local-Regional Recurrence - [47]
Abbas M, Habib M, Naveed M et al.. “The relevance of gastric cancer biomarkers in prognosis and pre- and post- chemotherapy in clinical practice.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2017). PMID: 28922727 ↗
L5NARRATIVE_REVIEWCited in: Local-Regional Recurrence - [48]
Reslinger V, Tranchart H, D'Annunzio E et al.. “Esophageal reconstruction by colon interposition after esophagectomy for cancer analysis of current indications, operative outcomes, and long-term survival.” Journal of surgical oncology (2015). PMID: 26699417 ↗
L5OTHERCited in: Local-Regional Recurrence - [49]
Shim HJ, Yun JY, Hwang JE et al.. “Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2011). PMID: 21431297 ↗
L5OTHERCited in: Local-Regional Recurrence - [50]
Kim MS, Yoo SY, Cho CK et al.. “Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer.” Journal of Korean medical science (2009). PMID: 19543514 ↗
L4CASE_SERIESCited in: Local-Regional Recurrence - [51]
Pavlakis N, Sjoquist KM, Martin AJ et al.. “Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27325864 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease - [52]
Yan C, Yang Z, Shi Z et al.. “Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial.” JAMA oncology (2026). PMID: 42166134 ↗
L1RCTCited in: Distant Metastatic Disease - [53]
Ishigami H, Kitayama J, Kaisaki S et al.. “Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19605503 ↗
L2NON_RANDOMIZED_TRIALCited in: Distant Metastatic Disease - [54]
Zhang J, Dai S, Zhou J et al.. “The survival and peritoneal metastasis of hyperthermic intraperitoneal chemotherapy in advanced gastric cancer: a systematic review and meta-analysis of randomized controlled trials.” International journal of surgery (London, England) (2025). PMID: 41731881 ↗
L1SR_MA_RCTCited in: Distant Metastatic Disease - [55]
Wang X, Yan O, Zhou J et al.. “Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42295761 ↗
L1RCTCited in: Distant Metastatic Disease - [56]
Nakayama I, Takahari D, Wakatsuki T et al.. “Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting.” ESMO open (2020). PMID: 32273288 ↗
L3RETROSPECTIVE_COHORTCited in: Distant Metastatic Disease - [57]
Yi W, Muhetaer K, Chen L et al.. “Immunotherapy combined with chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction cancer: systematic review and Bayesian network meta-analysis based on specific PD-L1 expression levels.” BMC cancer (2026). PMID: 42092825 ↗
L1SR_MA_RCTCited in: Distant Metastatic Disease - [58]
Bernards N, Creemers GJ, Nieuwenhuijzen GA et al.. “No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24121120 ↗
L5OTHERCited in: Distant Metastatic Disease - [59]
Adam-Artigues A, Arenas EJ, Arribas J et al.. “AXL - a new player in resistance to HER2 blockade.” Cancer treatment reviews (2023). PMID: 37864955 ↗
L5NARRATIVE_REVIEWCited in: Distant Metastatic Disease - [60]
Scagliotti GV, Novello S, von Pawel J. “The emerging role of MET/HGF inhibitors in oncology.” Cancer treatment reviews (2013). PMID: 23453860 ↗
L5NARRATIVE_REVIEWCited in: Distant Metastatic Disease - [61]
Alyami M, Hübner M, Grass F et al.. “Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications.” The Lancet. Oncology (2019). PMID: 31267971 ↗
L5NARRATIVE_REVIEWCited in: Distant Metastatic Disease - [62]
Jørgensen MS, Ainsworth AP, Fristrup CW et al.. “Prognostic value of baseline peritoneal fluid cytology in 224 patients with unresectable peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).” Human pathology (2025). PMID: 41401889 ↗
L2PROSPECTIVE_COHORTCited in: Distant Metastatic Disease - [63]
Endo S, Kimura Y, Sugimoto N et al.. “Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 41824192 ↗
L2NON_RANDOMIZED_TRIALCited in: Distant Metastatic Disease - [64]
Wang Z, Wang Y, Xu W et al.. “Weifuchun inhibits gastric cancer metastasis by inhibiting angiogenesis mediated by the miR-139-5p/CXCR4 axis.” Journal of ethnopharmacology (2026). PMID: 41577154 ↗
L1RCTCited in: Distant Metastatic Disease - [65]
Kroese TE, Jorritsma NKN, van Laarhoven HWM et al.. “Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.” Clinical and translational radiation oncology (2022). PMID: 36186924 ↗
L1RCTCited in: Oligometastatic Disease - [66]
Kroese TE, Bronzwaer S, van Rossum PSN et al.. “European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).” European journal of cancer (Oxford, England : 1990) (2024). PMID: 38678762 ↗
L1GUIDELINECited in: Oligometastatic Disease - [67]
Chiapponi C, Berlth F, Plum PS et al.. “Oligometastatic Disease in Upper Gastrointestinal Cancer - How to Proceed?” Visceral medicine (2017). PMID: 28612014 ↗
L1RCTCited in: Oligometastatic Disease - [68]
Kroese TE, van Laarhoven HWM, Schoppman SF et al.. “Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.” European journal of cancer (Oxford, England : 1990) (2023). PMID: 36947929 ↗
L2SR_COHORTCited in: Oligometastatic Disease - [69]
Yasufuku I, Tsuchiya H, Fujibayashi S et al.. “Oligometastasis of Gastric Cancer: A Review.” Cancers (2024). PMID: 38339424 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease - [70]
Kroese TE, Bronzwaer SFC, van Rossum PSN et al.. “Oligometastatic Esophagogastric Cancer: Does It Exist and How Do We Treat It?” Current oncology reports (2025). PMID: 39753813 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease - [71]
Kawakami S, Tsumura H, Satoh T et al.. “A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer.” Radiation oncology (London, England) (2022). PMID: 35379264 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease - [72]
Hara K, Cho H, Onodera A et al.. “Long-term treatment outcomes in gastric cancer with oligometastasis.” Annals of gastroenterological surgery (2023). PMID: 38250694 ↗
L4RETROSPECTIVE_COHORTCited in: Oligometastatic Disease - [73]
van Hootegem SJM, de Pasqual CA, Giacopuzzi S et al.. “Outcomes after Surgical Treatment of Oesophagogastric Cancer with Synchronous Liver Metastases: A Multicentre Retrospective Cohort Study.” Cancers (2024). PMID: 38398190 ↗
L4RETROSPECTIVE_COHORTCited in: Oligometastatic Disease - [74]
Yamaguchi T, Takashima A, Nagashima K et al.. “Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2023). PMID: 36695982 ↗
L4COHORTCited in: Oligometastatic Disease - [75]
Cui Y, Yu Y, Zheng S et al.. “Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA).” BMC cancer (2023). PMID: 37016303 ↗
L4PROSPECTIVE_COHORTCited in: Oligometastatic Disease - [76]
Haneder S, Budjan JM, Schoenberg SO et al.. “Dose-dependent changes in renal (1)H-/(23)Na MRI after adjuvant radiochemotherapy for gastric cancer.” Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2014). PMID: 25445156 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease - [77]
Jin P, Ji X, Tian Y. “Surgical management of oligometastatic disease in gastric cancer.” Clinics and research in hepatology and gastroenterology (2020). PMID: 32147440 ↗
L3COHORTCited in: Oligometastatic Disease - [78]
Yamaguchi H, Fukumitsu N, Numajiri H et al.. “The Japanese nationwide cohort data of proton beam therapy for liver oligometastasis in esophagogastric cancer patients.” Journal of radiation research (2023). PMID: 37697668 ↗
L4COHORTCited in: Oligometastatic Disease - [79]
Liu Z, Wang F, Zhang Y et al.. “Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report.” Frontiers in immunology (2024). PMID: 38361930 ↗
L4CASE_SERIESCited in: Oligometastatic Disease - [80]
Kroese TE, van Rossum PSN, Nilsson M et al.. “Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2022). PMID: 36184420 ↗
L5STUDY_PROTOCOLCited in: Oligometastatic Disease - [81]
Kim HI, Badgwell BD. “Peritoneal Oligometastasis in Gastric Cancer: Diagnostic Strategies, Patient Selection, and Emerging Therapeutic Approaches.” Journal of gastric cancer (2025). PMID: 40631471 ↗
L5NARRATIVE_REVIEWCited in: Oligometastatic Disease - [82]
Jung JO, Nienhüser H, Schleussner N et al.. “Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach.” International journal of molecular sciences (2020). PMID: 32023907 ↗
L5NARRATIVE_REVIEWCited in: Oligometastatic Disease - [83]
Shoda K, Kawaguchi Y, Maruyama S et al.. “Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer.” Annals of gastroenterological surgery (2025). PMID: 41199987 ↗
L5NARRATIVE_REVIEWCited in: Oligometastatic Disease - [84]
Shao L, Zhang H, He W et al.. “Advanced gastric cancer with metachronous intracranial oligometastases without recurrence after multidisciplinary team discussion and comprehensive treatment: a case report.” Frontiers in oncology (2023). PMID: 38023261 ↗
L4CASE_SERIESCited in: Oligometastatic Disease - [85]
Kang YK, Ryu MH, Park SH et al.. “Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29438463 ↗
L1RCTCited in: Prognosis of Recurrent Disease - [86]
Shitara K, Ito S, Misawa K et al.. “Genetic polymorphism of IGF-I predicts recurrence in patients with gastric cancer who have undergone curative gastrectomy.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21690232 ↗
L3COHORTCited in: Prognosis of Recurrent Disease - [87]
Kim JH, Kim HS, Seo WY et al.. “External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21566150 ↗
L4RETROSPECTIVE_COHORTCited in: Prognosis of Recurrent Disease - [88]
Sakuramoto S, Sasako M, Yamaguchi T et al.. “Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.” The New England journal of medicine (2007). PMID: 17978289 ↗
L1RCTCited in: Prognosis of Recurrent Disease - [89]
Ohtsu A, Ajani JA, Bai YX et al.. “Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24043745 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease - [90]
Bang YJ, Im SA, Lee KW et al.. “Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26282658 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease - [91]
Li J, Qin S, Xu J et al.. “Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23918952 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease - [92]
Türeci O, Sahin U, Schulze-Bergkamen H et al.. “A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31240302 ↗
L2NON_RANDOMIZED_TRIALCited in: Prognosis of Recurrent Disease